Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7763734 | 0.86 | APP (0.39) | CYP2C19BLMPTGS1PDE4ALMNA | |
| SCHEMBL1049496 | 0.75 | — | — | |
| SCHEMBL11831901 | 0.74 | PTGS1 (0.33) | CYP2C19BLMPTGS1PDE4ALMNA | |
| SCHEMBL8367008 | 0.73 | SLC22A6 (0.36) | — | |
| SCHEMBL1003412 | 0.73 | PTGS1 (0.32) | CYP2C19BLMPTGS1PDE4ALMNA | |
| SCHEMBL4929111 | 0.73 | SLC6A2 (0.36) | CYP2C19BLMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1046600 | 0.72 | — | — | |
| SCHEMBL3694045 | 0.71 | ENPEP (0.31) | CYP2C19BLMPTGS1PDE4ALMNA | |
| SCHEMBL1548289 | 0.71 | PTGS1 (0.31) | CYP2C19BLMPTGS1PDE4ALMNA | |
| SCHEMBL11145137 | 0.71 | PTGS1 (0.31) | CYP2C19BLMPTGS1PDE4ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120195937-A1 | POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZAE B SACCHARIDE VACCINES | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2012-08-02 | — | — | US | claimed |
| US-20060121059-A1 | Vaccine composition | GLAXOSMTHKLINE BIOLOGICALS, S.A. (BE) | 2006-06-08 | — | — | US | claimed |
| EP-1638597-A2 | POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZA B SACCHARIDE VACCINES | GlaxoSmithKline Biologicals S.A. (BE) | 2006-03-29 | — | — | EP | claimed |
| WO-2004110480-A2 | POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZA B SACCHARIDE VACCINES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2004-12-23 | — | — | WO | claimed |
| US-6610310-B2 | Immunology response; side effect reduction | AMERICAN CYANAMID COMPANY | 2003-08-26 | — | — | US | claimed |
| US-20030021793-A1 | POLYANIONIC POLYMERS AS ADJUVANTS FOR MUCOSAL IMMUNIZATION | ZOETIS SERVICES LLC | 2003-01-30 | — | — | US | claimed |
| EP-0934077-A2 | POLYANIONIC POLYMERS AS ADJUVANTS FOR MUCOSAL IMMUNIZATION | DIMMINACO AG/SA/LTD. (CH) | 1999-08-11 | — | — | EP | claimed |
| WO-1998017310-A2 | POLYANIONIC POLYMERS AS ADJUVANTS FOR MUCOSAL IMMUNIZATION | DIMMINACO AG/S.A./LTD. (CH) | 1998-04-30 | — | — | WO | claimed |
| US-20260091055-A1 | Methods of Managing Traumatic Brain Injury | UNIV EMORY (US) | 2026-04-02 | — | — | US | disclosed |
| US-12419905-B2 | Methods and compositions for the treatment of amyloid-related disorders | YALE UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2024059056-A1 | METHODS OF MANAGING TRAUMATIC BRAIN INJURY | EMORY UNIVERSITY (US) | 2024-03-21 | — | — | WO | disclosed |
| US-9364533-B2 | Polyanionic polymer adjuvants for Haemophilus influenzae B saccharide vaccines | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2016-06-14 | — | — | US | disclosed |
| US-20150037368-A1 | POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZAE B SACCHARIDE VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2015-02-05 | — | — | US | disclosed |
| US-20130337006-A1 | POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZAE B SACCHARIDE VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2013-12-19 | — | — | US | disclosed |
| US-20030021793-A1 | POLYANIONIC POLYMERS AS ADJUVANTS FOR MUCOSAL IMMUNIZATION | ZOETIS SERVICES LLC | 2003-01-30 | — | — | US | disclosed |
| EP-0934077-A2 | POLYANIONIC POLYMERS AS ADJUVANTS FOR MUCOSAL IMMUNIZATION | DIMMINACO AG/SA/LTD. (CH) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934077-A2 | POLYANIONIC POLYMERS AS ADJUVANTS FOR MUCOSAL IMMUNIZATION | DIMMINACO AG/SA/LTD. (CH) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998017310-A3 | Polyanionic polymers as adjuvants for mucosal immunization | DIMMINACO AG S A LTD (CH) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998017310-A2 | POLYANIONIC POLYMERS AS ADJUVANTS FOR MUCOSAL IMMUNIZATION | DIMMINACO AG/S.A./LTD. (CH) | 1998-04-30 | — | — | WO | disclosed |
| WO-1998017310-A2 | POLYANIONIC POLYMERS AS ADJUVANTS FOR MUCOSAL IMMUNIZATION | DIMMINACO AG/S.A./LTD. (CH) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091055-A1 | Methods of Managing Traumatic Brain Injury | SGMS2, SGMS1, S1PR2 | CYP2C19 3253/4885BLM 1304/4885PTGS1 444/4885 |
| US-12419905-B2 | Methods and compositions for the treatment of amyloid-related disorders | PRNP, APP, PSEN1 | CYP2C19 4828/4885BLM 1358/4885PTGS1 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.